Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SACS antisense RNA 1 (SACS-AS1) is a long non-coding RNA (lncRNA) transcribed from the SACS locus, oriented antisense to the SACS gene, and does not encode a protein. Antisense RNAs such as SACS-AS1 participate in regulating gene expression at multiple levels, including transcription, splicing, chromatin remodeling, and post-transcriptional regulation[1][2]. They may act in cis—affecting their neighboring sense gene by overlapping or proximity—or in trans, targeting distant loci or mRNAs or acting as competing endogenous RNAs (ceRNAs) to bind microRNAs, thereby influencing gene expression indirectly[1][2]. Many lncRNAs and antisense RNAs, depending on their genomic position and interactions, modulate chromatin state and gene responsiveness, or alter splicing by masking splice sites[1][2][3]. SACS-AS1 specifically has not been characterized as a therapeutic target, as current evidence does not link it directly to disease, drugs, or established biomarker roles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SACS antisense RNA 1 (SACS-AS1).